Ecto-5'-Nucleotidase | Adenosine turnover | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲


Target id: 1232

Nomenclature: Ecto-5'-Nucleotidase

Abbreviated Name: NT5E

Systematic Nomenclature: CD73

Family: Adenosine turnover

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: ON :     Ecto-5'-Nucleotidase has curated data in GtoImmuPdb

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - - NT5E 5'-nucleotidase ecto
Mouse - - Nt5e 5' nucleotidase, ecto
Rat - - Nt5e 5' nucleotidase, ecto
Previous and Unofficial Names
eN | eNT | NT5 | 5' nucleotidase (CD73) | ecto-5'-nucleotidase | 5'-nucleotidase, ecto (CD73) | 5' nucleotidase, ecto | 5' nucleotidase
Database Links
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
Enzyme Reaction
EC Number:
Rank order of affinity (Human)
adenosine 5'-monophosphate, 5'-GMP, 5'-inosine monophosphate, 5'-UMP > 5'-dAMP, 5'-dGMP

Download all structure-activity data for this target as a CSV file

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
PSB-0963 Rn Inhibition 6.8 pKi 2
pKi 6.8 (Ki 1.5x10-7 M) [2]
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Units Reference
oleclumab Hs Binding 11.4 pKd 4
pKd 11.4 (Kd 4.2x10-12 M) [4]
General Comments
CD73 is membrane-bound extracellular enzyme that, together with CD39, plays a major role in promoting immunosuppression through the pathway that degrades adenosine triphosphate (ATP) into adenosine. CD73 performs the terminal catalytic step in conversion to adenosine. It is overexpressed in several cancer types, and this has been linked with poor prognosis in certain cancers [6-9,11,13]. Adenosine accumulation driven by this pathway in the tumour microenvironment causes immune suppression, is pro-angiogenic and stimulates tumour metastasis.


Show »

1. Antonioli L, Pacher P, Vizi ES, Haskó G. (2013) CD39 and CD73 in immunity and inflammation. Trends Mol Med, 19 (6): 355-67. [PMID:23601906]

2. Baqi Y, Lee SY, Iqbal J, Ripphausen P, Lehr A, Scheiff AB, Zimmermann H, Bajorath J, Müller CE. (2010) Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J. Med. Chem., 53 (5): 2076-86. [PMID:20146483]

3. Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A. (2013) ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene, 32 (14): 1743-51. [PMID:22751118]

4. Geoghegan JC, Diedrich G, Lu X, Rosenthal K, Sachsenmeier KF, Wu H, Dall'Acqua WF, Damschroder MM. (2016) Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action. MAbs, 8 (3): 454-67. [PMID:26854859]

5. Häusler SF, Del Barrio IM, Diessner J, Stein RG, Strohschein J, Hönig A, Dietl J, Wischhusen J. (2014) Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res, 6 (2): 129-39. [PMID:24489992]

6. Leclerc BG, Charlebois R, Chouinard G, Allard B, Pommey S, Saad F, Stagg J. (2016) CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer. Clin. Cancer Res., 22 (1): 158-66. [PMID:26253870]

7. Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, Stagg J. (2013) CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc. Natl. Acad. Sci. U.S.A., 110 (27): 11091-6. [PMID:23776241]

8. Lu XX, Chen YT, Feng B, Mao XB, Yu B, Chu XY. (2013) Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma. World J. Gastroenterol., 19 (12): 1912-8. [PMID:23569336]

9. Ren ZH, Lin CZ, Cao W, Yang R, Lu W, Liu ZQ, Chen YM, Yang X, Tian Z, Wang LZ et al.. (2016) CD73 is associated with poor prognosis in HNSCC. Oncotarget, 7 (38): 61690-61702. [PMID:27557512]

10. Stagg J. (2012) The double-edge sword effect of anti-CD73 cancer therapy. Oncoimmunology, 1 (2): 217-218. [PMID:22720247]

11. Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D et al.. (2012) NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br. J. Cancer, 106 (8): 1446-52. [PMID:22454080]

12. Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, Zhang B. (2011) CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J. Clin. Invest., 121 (6): 2371-82. [PMID:21537079]

13. Wu XR, He XS, Chen YF, Yuan RX, Zeng Y, Lian L, Zou YF, Lan N, Wu XJ, Lan P. (2012) High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J Surg Oncol, 106 (2): 130-7. [PMID:22287455]


Show »

How to cite this page

Detlev Boison.
Adenosine turnover: Ecto-5'-Nucleotidase. Last modified on 20/09/2017. Accessed on 18/01/2019. IUPHAR/BPS Guide to PHARMACOLOGY,